TITLE

Tetrahydrobiopterin Pathway may Provide Novel Molecular Targets for Acute and Long Term Efficacy of Mood-Regulating Drugs

AUTHOR(S)
McHugh, Patrick C.
PUB. DATE
September 2010
SOURCE
Current Pharmacogenomics & Personalized Medicine;Sep2010, Vol. 8 Issue 3, p174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Existing treatments for depression usually take several weeks to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement or are treatment refractory even after long-term drug administration. Moreover, the increased risk of suicide is a serious public health concern that can occur particularly during the initial stages of antidepressant pharmacotherapy. Thus, there is an urgent need for therapeutics with improved efficacy that can exert their effects within hours or days of their administration. The pteridine tetrahydrobiopterin (BH4) is an essential co-factor for production of many neurotransmitters including serotonin. Given the pivotal role of BH4 in several processes fundamental to the pathobiology of mood disorders and the mechanisms of action of mood-regulating drugs, it is surprising that only a few studies have examined the potential role of BH4 pathway genes in individual variability in susceptibility to mood disorders and their treatment outcomes. Although previous studies have examined BH4 in these contexts, there were methodological shortcomings, as well as conflicting findings. However, more recent studies have provided new evidence for the importance of the BH4 pathway in mood disorders and their treatment. For example, the recent finding that the SSRI antidepressant paroxetine substantially affects the level of the protein sepiapterin reductase, which catalyzes the final step in the biosynthesis of BH4, in neural cells, has suggested a need to re-examine the BH4 pathway in the context of the pathobiology of mood disorders and, more importantly, as a potential target for mood-regulating drugs.
ACCESSION #
55605722

 

Related Articles

  • Novel glutamatergic drugs for the treatment of mood disorders. Lapidus, Kyle A. B.; Soleimani, Laili; Murrough, James W. // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p1101 

    Mood disorders are common and debilitating, resulting in a significant public health burden. Current treatments are only partly effective and patients who have failed to respond to trials of existing antidepressant agents (eg, those who suffer from treatment-resistant depression [TRD]) require...

  • Mood Manipulators. Howard, Lucy; Begun, Bret; Meadows, Susannah; Stroup, Katherine // Newsweek;10/16/2000, Vol. 136 Issue 16, p10 

    Discusses a non-pill treatment for depression. Use of the Vagal Nerve Stimulator which is implanted into the brain as a treatment; Tests of the Stimulator which found that the electrical pulses of the implant seem to affect the same area of the brain as antidepressants; Implications for...

  • Pharmacotherapy for Child and Adolescent Mood Disorders. Singh, Manpreet K.; Pfeifer, Jonathan C.; Barzman, Drew; Kowatch, Robert A.; DelBello, Melissa P. // Psychiatric Annals;Jul2007, Vol. 37 Issue 7, p465 

    The article presents a summary of controlled pharmacotherapy trials for the treatment of mood disorders in children and adolescents. This entry also includes information on the pharmacotherapy for depressive disorders and bipolar disorders. It also discusses pharmacotherapy of children at...

  • Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. Fava, Giovanni A.; Ruini, Chiara; Sonino, Nicoletta // CNS Drugs;2003, Vol. 17 Issue 15, p1109 

    The chronic and recurrent nature of major depressive disorder is receiving increasing attention. Approximately eight of ten people experiencing a major depressive episode will have at least one more episode during their lifetime, i.e. recurrent major depressive disorder. In the 1990s, prolonged...

  • Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments. Simon, Neal G.; Guillon, Christophe; Fabio, Karine; Heindel, Ned D.; Lu, Shi-fang; Miller, Marvin; Ferris, Craig F.; Brownstein, Michael J.; Garripa, Carrie; Koppel, Gary A. // Recent Patents on CNS Drug Discovery;Jun2008, Vol. 3 Issue 2, p77 

    A compelling case for the potential utility of vasopressin (AVP) antagonists as a novel therapeutic class for the treatment of stress-related affective illness has emerged based on observations in depressed individuals, findings in animal models of anxiety and depression, and an understanding of...

  • Bupropion.  // AHFS Consumer Medication Information;Dec2014, p1 

    Bupropion (Aplenzin, Wellbutrin, Wellbutrin SR, Wellbutrin XL) is used to treat depression. Bupropion (Wellbutrin XL) is also used to treat seasonal affective disorder (SAD; episodes of depression that occur in the fall and winter each year). Bupropion (Zyban) is used to help people stop...

  • Issues in treating depression in primary care. Horn, Neil R. // CME: Continuing Medical Education;Apr2012, Vol. 30 Issue 4, p131 

    The article focuses on new information about the effectiveness of antidepressants (ADs) and psychological therapies for treating depression. In persons with mild depression, it is reasonable to postpone the use of ADs and to offer psychological therapies. The preferred goal of treatment is...

  • Antidepressant Drug Effects and Depression Severity. Fournier, Jay C.; DeRubeis, Robert J.; Hollon, Steven D.; Dimidjian, Sona; Amsterdam, Jay D.; Shelton, Richard C.; Fawcett, Jan // JAMA: Journal of the American Medical Association;1/6/2010, Vol. 303 Issue 1, p47 

    The article focuses on a study which estimated the relative benefit of medication versus placebo across a wide range of initial symptom severity in patients diagnosed with depression using information from several databases, which include the Cochrane Library database. The study observed that as...

  • Pharmacologic Treatment of Psychotic Depression. Kripke, Clarissa // American Family Physician;6/1/2006, Vol. 73 Issue 11, p1935 

    The article discusses a study which suggested a treatment for depression with psychotic features. An antidepressant such as imipramine or sertraline was recommended for treating psychotic depression. Details of how the study was conducted are given. Importantly, this article states the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics